Kairos Pharma announces 1-for-7 reverse stock split effective Sept 1, 2026

Kairos Pharma, LTD.

1-for-7 reverse split effective Sep 1, 2026 at 12:01 a.m. ET; trading under KAPA with new CUSIP 48301N203.
Every 7 shares reclassified to 1; no fractional shares, holders round up to nearest whole share.
Proportional adjustments to warrants, convertible notes, and equity awards; authorized shares unchanged.
Split intended to raise per-share price and maintain compliance with NYSE American listing requirements.
VStock Transfer is exchange agent; holders in book-entry or street name need not take any action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.